SPORE for Translational Approaches to Brain Cancer

概述：摘要 西北脑瘤孢子的总体目标是改善脑瘤的治疗结果 病人。关于脑瘤发病率的统计数据表明，超过2.3万人将被诊断为脑瘤 2017年，美国将有大约17,000人死于脑瘤。不同的初选 脑内肿瘤中，以胶质母细胞瘤(GBM)最为常见。接受标准护理的GBM患者 治疗的中位生存期为15个月，5年生存率极其罕见。发展中的进步 对于这种致命的肿瘤，更好的治疗方法令人失望。造成这种缺乏治疗的一个主要因素 改善是这种癌症发生的器官的微妙性质。有很大的局限性 GBM患者的外科治疗力度有多大，全身给药的疗效如何 由于接触大脑的途径有限，治疗方法经常受到影响。为了解决公共卫生问题， 与胶质母细胞瘤有关，我们组建了一支才华横溢的调查团队，拥有广泛的 脑瘤研究和治疗的背景。这个团队的所有成员都有职业记录 表明他们成功地指导了他们自己的研究计划。大约3年前，这些教职员工发起了 小组互动为了将团队科学方法应用于GBM的研究和治疗， 为此，需要采取多学科方法，以取得有意义的进展。

OVERVIEW: SUMMARY The overall objective of the Northwestern Brain Tumor SPORE is to improve outcomes for brain tumor patients. Statistics on brain tumor incidence indicate that more than 23,000 people will be diagnosed with a brain tumor in the U.S. in 2017, and approximately 17,000 will succumb to their disease. Of the various primary intracerebral neoplasms, glioblastoma (GBM) is the most common. GBM patients that receive standard-of-care treatment have a median survival of 15 months, and 5-year survival is extremely rare. Progress in developing better treatments for this lethal tumor has been disappointing. A major contributor to this lack of therapeutic improvement is the delicate nature of the organ in which this cancer occurs. There are significant limitations to how aggressively GBM patients can be treated surgically, and the efficacy of systemically administered therapies are often compromised due to limited access to the brain. To address the public health problem that is associated with glioblastoma, we have assembled a talented team of investigators with extensive backgrounds in brain tumor research and therapy. All members of this team have professional records indicating success in directing their own programs of research. Some 3+ years ago, these faculty initiated group interactions in order to bring a team science approach to bear upon the study and treatment of GBM, and for which a multidisciplinary approach is needed for achieving meaningful progress.